|
1
|
Torre LA, Sauer AM, Chen MS Jr,
Kagawa-Singer M, Jemal A and Siegel RL: Cancer statistics for Asian
Americans, native Hawaiians, and Pacific Islanders, 2016:
Convergence of incidence between males and females. CA Cancer J
Clin. 66:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina-Sánchez P and Lujambio A:
Strategies for HCC target discovery. Aging (Albany NY).
9:1088–1089. 2017.PubMed/NCBI
|
|
3
|
Azumi M, Suda T, Terai S, Terai K and
Akazawa K: Prognostic impact of indocyanine green plasma
disappearance rate in hepatocellular carcinoma patients after
radiofrequency ablation: A prognostic nomogram study. Intern Med.
56:1001–1007. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu SJ: A concise review of updated
guidelines regarding the management of hepatocellular carcinoma
around the world: 2010–2016. Clin Mol Hepatol. 22:7–17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin J, Shen A, Chen H, Liao J, Xu T, Liu
L, Lin J and Peng J: Nitidine chloride inhibits hepatic cancer
growth via modulation of multiple signaling pathways. BMC Cancer.
14:7292017. View Article : Google Scholar
|
|
6
|
Liu Z, Wang T, Zhang Z, Tang S, Feng S,
Yue M, Hu M, Xuan L and Chen Y: Survivin downregulation using siRNA
nanoliposomes inhibits cell proliferation and promotes the
apoptosis of MHCC-97H hepatic cancer cells: An in vitro and
in vivo study. Oncol Lett. 13:2723–2730. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kelley RK, Verslype C, Cohn AL, Yang TS,
Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, et al:
Cabozantinib in hepatocellular carcinoma: Results of a phase 2
placebo-controlled randomized discontinuation study. Ann Oncol.
28:528–534. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Rajabi R, Patel S, Ketchum NS, Jaime
NA, Lu TW, Pollock BH and Mahalingam D: Comparative dosing and
efficacy of sorafenib in hepatocellular cancer patients with
varying liver dysfunction. J Gastrointest Oncol. 6:259–267.
2017.
|
|
9
|
Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T,
Tsung A, Tohme S, Huang H, Zhang Q, et al: Intracellular autocrine
VEGF signaling promotes EBDC cell proliferation, which can be
inhibited by Apatinib. Cancer Lett. 373:193–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roviello G, Ravelli A, Polom K, Petrioli
R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A
novel receptor tyrosine kinase inhibitor for the treatment of
gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li F, Liao Z, Zhao J, Zhao G, Li X, Du X,
Yang Y and Yang J: Efficacy and safety of Apatinib in stage IV
sarcomas: Experience of a major sarcoma center in China.
Oncotarget. 8:64471–64480. 2017.PubMed/NCBI
|
|
12
|
Li K and Li J: Current molecular targeted
therapy in advanced gastric cancer: A comprehensive review of
therapeutic mechanism, clinical trials, and practical application.
Gastroenterol Res Pract. 2016:41056152016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H: Apatinib for molecular targeted
therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L,
Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of
Apatinib in non-triple-negative metastatic breast cancer. BMC
Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Langer CJ, Mok T and Postmus PE: Targeted
agents in the third-/fourth-line treatment of patients with
advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer
Treat Rev. 39:252–260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kou P, Zhang Y, Shao W, Zhu H, Zhang J,
Wang H, Kong L and Yu J: Significant efficacy and well safety of
apatinib in an advanced liver cancer patient: a case report and
literature review. Oncotarget. 8:20510–20515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shrivastava S, Jeengar MK, Reddy VS, Reddy
GB and Naidu VG: Anticancer effect of celastrol on human triple
negative breast cancer: Possible involvement of oxidative stress,
mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol
Pathol. 98:313–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH
and Chun KH: Celastrol inhibits gastric cancer growth by induction
of apoptosis and autophagy. BMB Rep. 47:697–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan
R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al:
Celastrol suppresses growth and Induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2
signaling cascade in vitro and in vivo. Cancer Prev Res. 5:631–643.
2012. View Article : Google Scholar
|
|
20
|
Li H, Li Y, Liu D, Sun H and Liu J:
miR-224 is critical for celastrol-induced inhibition of migration
and invasion of hepatocellular carcinoma cells. Cell Physiol
Biochem. 32:448–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chakravarthy R, Clemens MJ, Pirianov G,
Perdios N, Mudan S, Cartwright JE and Elia A: Role of the eIF4E
binding protein 4E-BP1 in regulation of the sensitivity of human
pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.
Biol Cell. 105:414–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang S and Liu G: Targeting the
Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett.
13:1041–1047. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Popper HH: Progression and metastasis of
lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arvelo F, Sojo F and Cotte C: Tumour
progression and metastasis. Ecancermedicalscience. 10:6172016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vilanova G, Colominas I and Gomez H: A
mathematical model of tumour angiogenesis: Growth, regression and
regrowth. J R Soc Interface. 14:201609182017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.PubMed/NCBI
|
|
27
|
Bertino G, Demma S, Ardiri A, Proiti M,
Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M,
Malaguarnera M and Di Carlo I: Hepatocellular carcinoma: Novel
molecular targets in carcinogenesis for future therapies. Biomed
Res Int. 2014:2036932014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao Y and Adjei AA: Targeting
angiogenesis in cancer therapy: Moving beyond vascular endothelial
growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al-Abd AM, Alamoudi AJ, Abdel-Naim AB,
Neamatallah TA and Ashour OM: Anti-angiogenic agents for the
treatment of solid tumors: Potential pathways, therapy and current
strategies-A review. J Adv Res. 8:591–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding J, Chen X, Gao Z, Dai X, Li L, Xie C,
Jiang H, Zhang L and Zhong D: Metabolism and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor apatinib in humans. Drug Metab Dispos. 41:1195–1210.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schulte N, Ebert MP and Härtel N: Gastric
cancer: New drugs-New strategies. Gastrointest Tumors. 1:180–194.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roviello G, Ravelli A, Fiaschi AI,
Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR,
Fox SB and Generali D: Apatinib for the treatment of gastric
cancer. Expert Rev Gastroenterol Hepatol. 10:887–892.
2016.PubMed/NCBI
|
|
34
|
Venkatesha SH and Moudgil KD: Celastrol
and its role in controlling chronic diseases. Adv Exp Med Biol.
928:267–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Z, Zhai Z and Du X: Celastrol
inhibits migration and invasion through blocking the NF-κB pathway
in ovarian cancer cells. Exp Ther Med. 14:819–824. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Figueiredo SAC, Salvador JAR, Cortés R and
Cascante M: Novel celastrol derivatives with improved selectivity
and enhanced antitumour activity: Design, synthesis and biological
evaluation. Eur J Med Chem. 138:422–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brahmbhatt H, Uehling D, Al-Awar R, Leber
B and Andrews D: Small molecules reveal an alternative mechanism of
Bax activation. Boichem J. 473:1073–1083. 2016. View Article : Google Scholar
|
|
38
|
Luna-Vargas MPA and Chipuk JE:
Physiological and pharmacological control of BAK, BAX, and
beyond.trends. Cell Biol. 26:906–917. 2016.
|
|
39
|
Todt F, Cakir Z, Reichenbach F,
Emschermann F, Lauterwasser J, Kaiser A, Ichim G, Tait SW, Frank S,
Langer HF and Edlich F: Differential retrotranslocation of
mitochondrial Bax and Bak. EMBO J. 34:67–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burgess JT, Bolderson E, Adams MN, Baird
AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ and Richard DJ:
Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic
response. Cell Death Dis. 7:e24692016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kochetkova EY, Blinova GI, Bystrova OA,
Martynova MG, Pospelov VA and Pospelova TV: Targeted elimination of
senescent Ras-transformed cells by suppression of MEK/ERK pathway.
Aging (Albany NY). 9:2352–2375. 2017.PubMed/NCBI
|
|
42
|
Adlung L, Kar S, Wagner MC, She B,
Chakraborty S, Bao J, Lattermann S, Boerries M, Busch H, Wuchter P,
et al: Protein abundance of AKT and ERK pathway components governs
cell type-specific regulation of proliferation. Mol Syst Biol.
13:9042017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ewald F, Nörz D, Grottke A, Bach J,
Herzberger C, Hofmann BT, Nashan B and Jücker M: Vertical targeting
of AKT and mTOR as well as Dual targeting of AKT and MEK signaling
is synergistic in hepatocellular carcinoma. J Cancer. 6:1195–1205.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Renault TT and Chipuk JE: Death upon a
kiss: Mitochondrial outer membrane composition and organelle
communication govern sensitivity to BAK/BAX-dependent apoptosis.
Chem Biol. 21:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
McIlwain DR, Berger T and Mak TW: Caspase
functions in cell death and disease. Cold Spring Harb Perspect
Biol. 7:a0086562013.
|
|
46
|
Wu W, Zhang D, Pan D, Zuo G, Ren X and
Chen S: Downregulation of vascular endothelial growth factor
receptor-2 under oxidative stress conditions is mediated by
β-transduction repeat-containing protein via glycogen synthase
kinase-3β signaling. Int J Mol Med. 37:911–920. 2016. View Article : Google Scholar : PubMed/NCBI
|
